ImmunoGen (IMGN) has an average broker rating of 2.61, which is interpreted as a Hold, as rated by 7 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
ImmunoGen (IMGN) : 6 investment research analysts covering ImmunoGen (IMGN) have an average price target of $6.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $9 and the lowest target is $3 for the short term. Analysts expect the variance to be within $2.4 of the average price.
Shares of ImmunoGen, Inc. rose by 2.61% in the last five trading days and 11.74% for the last 4 weeks. ImmunoGen, Inc. has dropped 45.1% during the last 3-month period . Year-to-Date the stock performance stands at -76.86%. ImmunoGen (NASDAQ:IMGN): stock turned positive on Tuesday. Though the stock opened at $3.13, the bulls momentum made the stock top out at $3.1799 level for the day. The stock recorded a low of $3.07 and closed the trading day at $3.14, in the green by 0.96%. The total traded volume for the day was 655,521. The stock had closed at $3.11 in the previous days trading.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.